Nature Biotechnology’s academic spinouts of 2019 | Nature Biotechnology
Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report.
Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report. Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and…
saved by
related reading
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- GC-Mainarep.med.harvard.edu
- An Open Letter in Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeepingscreendna.org
- List of Biotechnology Companies to Watch – AI Expanded Versionsubstack.com
- Asimov — Intelligent Designasimov.com
- RNA-based therapeutics: an overview and prospectusnature.com
- Neion Bioneionbio.com
- Reasons to be pessimistic (and optimistic) on the future of biosecurityowlposting.com
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
- AlphaProteo generates novel proteins for biology and health researchdeepmind.google
- The Frontier in 2025renaissancephilanthropy.org
- Making Vaccine — LessWronglesswrong.com